Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Investing Activities: 2014-2024

Historic Cash from Investing Activities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to -$219.8 million.

  • Syndax Pharmaceuticals' Cash from Investing Activities fell 16.60% to $72.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.5 million, marking a year-over-year decrease of 283.89%. This contributed to the annual value of -$219.8 million for FY2024, which is 286.87% down from last year.
  • Syndax Pharmaceuticals' Cash from Investing Activities amounted to -$219.8 million in FY2024, which was down 286.87% from $117.6 million recorded in FY2023.
  • Syndax Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $117.6 million during FY2023, with a 5-year trough of -$219.8 million in FY2024.
  • Its 3-year average for Cash from Investing Activities is -$96.1 million, with a median of -$186.2 million in 2022.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 1,215.17% in 2020, then skyrocketed by 163.17% in 2023.
  • Syndax Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$142.5 million in 2020, then skyrocketed by 71.32% to -$40.9 million in 2021, then slumped by 355.53% to -$186.2 million in 2022, then skyrocketed by 163.17% to $117.6 million in 2023, then plummeted by 286.87% to -$219.8 million in 2024.